Potential Role of M. tuberculosis Specific IFN-γ and IL-2 ELISPOT Assays in Discriminating Children with Active or Latent Tuberculosis

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Chiappini, Elena ^a   della Bella, Chiara ^b   Bonsignori, Francesca ^a   Sollai, Sara ^a   Amedei, Amedeo ^b   Galli, Luisa ^a   Niccolai, Elena ^b   Del Prete, Gianfranco ^b   Singh, Mahavir ^c   D'Elios, Mario M ^b   de Martino, Maurizio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c LIONEX DIAGNOSTICS AND THERAPEUTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CULTURE FILTRATE PROTEIN 10; EARLY SECRETORY ANTIGENIC TARGET 6; GAMMA INTERFERON; INTERLEUKIN 2; MYCOBACTERIUM ANTIGEN; PROTEIN AG85B; PROTEIN ALADH; PROTEIN HSPX; PROTEIN PSTS1; PROTEIN TB 10.3; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY;

ANTIGENS, BACTERIAL; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSPOT ASSAY; HUMANS; INFANT; INTERFERON-GAMMA; INTERLEUKIN-2; LATENT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 84866978332     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046041     Document Type: Article

References (20)

1. Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y, Hatherill M, Moyo S, et al. (2011) The utility of an interferon gamma release assay for diagnosis of latent tuberculosis infection and disease in children: a systematic review and meta-analysis. Pediatr Infect Dis J 30: 694-700.
2. Chiappini E, Fossi F, Bonsignori F, Sollai S, Galli L, et al. (2012) Utility of Interferon-γ Release Assay Results to Monitor Anti-Tubercular Treatment in Adults and Children. Clin Ther 2012 Apr 16. [Epub ahead of print].
3. Pai M, Zwerling A, Menzies D, (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149: 177-84.
4. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, et al. (2010) IGRA Expert Committee; Centers for Disease Control and Prevention (CDC).Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection- United States, 2010. MMWR Recomm Rep 59: 1-25.
5. Sun L, Xiao J, Miao Q, Feng WX, Wu XR, et al. (2011) Interferon gamma release assay in diagnosis of pediatric tuberculosis: a meta-analysis. FEMS Immunol Med Microbiol 63: 165-73.
6. Mandalakas AM, Detjen AK, Hesseling AC, Benedetti A, Menzies D, (2011) Interferon-gamma release assays and childhood tuberculosis: systematic review and meta-analysis. Int J Tuberc Lung Dis 15: 1018-32.
7. American Academy of Pediatrics. (2009) [Tuberculosis]. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2009 Report of the Committee on Infectious Diseases. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics; 680-701.
8. Amanatidou V, Syridou G, Mavrikou M, Tsolia MN, (2012) Latent tuberculosis infection in children: diagnostic approaches. Eur J Clin Microbiol Infect Dis 2012 Jan 4. [Epub ahead of print].
9. Biselli R, Mariotti S, Sargentini V, Sauzullo I, Lastilla M, et al. (2010) Detection of interleukin-2 in addition to interferon-gamma discriminates active tuberculosis patients, latently infected individuals, and controls. Clin Microbiol Infect 16: 1282-4.
10. Millington KA, Fortune SM, Low J, Garces A, Hingley-Wilson SM, (2011) Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 108: 5730-5.
11. Vilaplana C, Ruiz-Manzano J, Gil O, Cuchillo F, Montané E, et al. (2008) The tuberculin skin test increases the responses measured by T cell interferon-gamma release assays. Scand J Immunol 67: 610-7.
12. Benagiano M, Munari F, Ciervo A, Amedei A, Paccani SR, et al. (2012) Chlamydophila pneumoniae phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. Proc Natl Acad Sci U S A 109: 1222-7.
13. Kampmann B, Whittaker E, Williams A, Walters S, Gordon A, et al. (2009) Martinez-Alier N, Williams B, Crook AM, Hutton AM, Anderson ST. Interferon-gamma release assays do not identify more children with active tuberculosis than the tuberculin skin test. Eur Respir J 33: 1374-82.
14. Hogarth PJ, Logan KE, Ferraz JC, Hewinson RG, Chambers MA, (2006) Protective efficacy induced by Mycobacterium bovis bacille Calmette-Guèrin can be augmented in an antigen independent manner by use of non-coding plasmid DNA. Vaccine 24: 95-101.
15. Takamura S, Matsuo K, Takebe Y, Yasutomi Y, (2005) Ag85B of mycobacteria elicits effective CTL responses through activation of robust Th1 immunity as a novel adjuvant in DNA vaccine. J Immunol 175: 2541-7.
16. Skjøt RL, Brock I, Arend SM, Munk ME, Theisen M, et al. (2002) Epitope mapping of the immunodominant antigen TB10.4 and the two homologous proteins TB10.3and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect Immun 70: 5446-53.
17. Agren D, Stehr M, Berthold CL, Kapoor S, Oehlmann W, et al. (2008) Singh M, Schneider G.Three-dimensional structures of apo- and holo-L-alanine dehydrogenase from Mycobacterium tuberculosis reveal conformational changes upon coenzyme binding. J Mol Biol 377: 1161-73.
18. Krummel B, Strassburg A, Ernst M, Reiling N, Eker B, et al. (2010) Potential role for IL-2 ELISpot in differentiating recent and remote infection in tuberculosis contact tracing. PLoS One 5: e11670.
19. Mori T, (2009) Usefulness of interferon-gamma release assays for diagnosing TB infection and problems with these assays. J Infect Chemother 15: 143-55.
20. Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, et al. (2006) VACSEL Study Group. Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacteriumtuberculosis. Clin Vaccine Immunol 13: 179-86.